{
    "clinical_study": {
        "@rank": "87158", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Day 1:\nGLASSIA at 0.04 mL/kg/min\nPlacebo at 0.2 mL/kg/min\nDay 15:\nGLASSIA at 0.2 mL/kg/min\nPlacebo at 0.04 mL/kg/min"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Day 1:\nGLASSIA at 0.2 mL/kg/min\nPlacebo at 0.04 mL/kg/min\nDay 15:\nGLASSIA at 0.04 mL/kg/min\nPlacebo at 0.2 mL/kg/min"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study was to generate sufficient safety and tolerability information in\n      support of an increase in the infusion rate of intravenous GLASSIA in the prescribing\n      information from 0.04 to 0.2 mL/kg/min."
        }, 
        "brief_title": "GLASSIA Infusion Rate Study", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "Day 1:\nGLASSIA at 0.04 mL/kg/min\nPlacebo at 0.2 mL/kg/min\nDay 15:\nGLASSIA at 0.2 mL/kg/min\nPlacebo at 0.04 mL/kg/min\nPlacebo: Human albumin 2.5%: Intravenous administration", 
                            "title": "Cohort 1"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "Day 1:\nGLASSIA at 0.2 mL/kg/min\nPlacebo at 0.04 mL/kg/min\nDay 15:\nGLASSIA at 0.04 mL/kg/min\nPlacebo at 0.2 mL/kg/min\nPlacebo: Human albumin 2.5%: Intravenous administration", 
                            "title": "Cohort 2"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "15"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "15"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "30"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "8", 
                                                "@value": "27"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "13", 
                                                "@value": "29"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "11", 
                                                "@value": "28"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "3"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "4"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "7"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "12"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "11"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "23"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "15"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "15"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "30"
                                            }
                                        ]
                                    }, 
                                    "sub_title": "United States"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }, 
                "population": "Safety Analysis Set"
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "PI may not publish without the prior written consent of Sponsor"
            }, 
            "limitations_and_caveats": "Simultaneous infusion of GLASSIA and placebo did not allow adverse events (AEs) to be unquestionably ascribed to either one. Any observed AE which was assessed by the investigator as related to treatment was conservatively attributed to GLASSIA.", 
            "outcome_list": {
                "outcome": [
                    {
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "title": "GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "title": "GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "30"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "30"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)", 
                                    "units": "Infusions"
                                }
                            ]
                        }, 
                        "population": "Safety Analysis Set", 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1 and Day 15", 
                        "title": "Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Number of infusions with temporally associated AEs with an onset time during or within 1 hour of infusion completion, regardless of causality assessment", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "title": "GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "title": "GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "30"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "30"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "1"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Number of infusions with temporally associated AEs with an onset time during or within 1 hour of infusion completion, regardless of causality assessment", 
                                    "param": "Number", 
                                    "title": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion", 
                                    "units": "Infusions"
                                }
                            ]
                        }, 
                        "population": "Safety Analysis Set", 
                        "safety_issue": "Yes", 
                        "time_frame": "Within 1 hour of infusion completion", 
                        "title": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Number of infusions with temporally associated AEs with an onset time during or within 24 hours of infusion completion, regardless of causality assessment", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "title": "GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "title": "GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "30"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "30"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "5"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Number of infusions with temporally associated AEs with an onset time during or within 24 hours of infusion completion, regardless of causality assessment", 
                                    "param": "Number", 
                                    "title": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion", 
                                    "units": "Infusions"
                                }
                            ]
                        }, 
                        "population": "Safety Analysis Set", 
                        "safety_issue": "Yes", 
                        "time_frame": "Within 24 hours of the end of infusion", 
                        "title": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Number of infusions with temporally associated AEs with an onset time during or within 72 hours of infusion completion, regardless of causality assessment", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "title": "GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "title": "GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "30"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "30"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "7"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "5"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Number of infusions with temporally associated AEs with an onset time during or within 72 hours of infusion completion, regardless of causality assessment", 
                                    "param": "Number", 
                                    "title": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion", 
                                    "units": "Infusions"
                                }
                            ]
                        }, 
                        "population": "Safety Analysis Set", 
                        "safety_issue": "Yes", 
                        "time_frame": "Within 72 hours of the end of infusion", 
                        "title": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Number of AEs that occurred during an infusion and were deemed related to study product administration", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "title": "GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "title": "GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "30"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "30"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Number of AEs that occurred during an infusion and were deemed related to study product administration", 
                                    "param": "Number", 
                                    "title": "Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion", 
                                    "units": "adverse events"
                                }
                            ]
                        }, 
                        "population": "Safety Analysis Set", 
                        "safety_issue": "Yes", 
                        "time_frame": "Day 1 and Day 15", 
                        "title": "Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Number of AEs that occurred between 72 hours and 14 day following an infusion and were deemed related to study product administration", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "title": "GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "title": "GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "30"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "30"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "0"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Number of AEs that occurred between 72 hours and 14 day following an infusion and were deemed related to study product administration", 
                                    "param": "Number", 
                                    "title": "Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion", 
                                    "units": "adverse events"
                                }
                            ]
                        }, 
                        "population": "Safety Analysis Set", 
                        "safety_issue": "Yes", 
                        "time_frame": "72 hours post infusion to 14 days post infusion", 
                        "title": "Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Number of participants with seroconversion", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "title": "All Study Participants"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "30"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "HAV"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "HBV"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "HCV"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "PVB19"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "HIV"
                                            }
                                        ]
                                    }, 
                                    "description": "Number of participants with seroconversion", 
                                    "param": "Number", 
                                    "title": "Number of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Safety Analysis Set", 
                        "safety_issue": "Yes", 
                        "time_frame": "105 days", 
                        "title": "Number of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "Day 1:\nGLASSIA at 0.04 mL/kg/min\nPlacebo at 0.2 mL/kg/min\nDay 15:\nGLASSIA at 0.2 mL/kg/min\nPlacebo at 0.04 mL/kg/min\nAlpha1-proteinase inhibitor: GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.\nPlacebo: Human albumin 2.5%: Intravenous administration", 
                            "title": "Cohort 1"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "Day 1:\nGLASSIA at 0.2 mL/kg/min\nPlacebo at 0.04 mL/kg/min\nDay 15:\nGLASSIA at 0.04 mL/kg/min\nPlacebo at 0.2 mL/kg/min\nAlpha1-proteinase inhibitor: GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.\nPlacebo: Human albumin 2.5%: Intravenous administration", 
                            "title": "Cohort 2"
                        }
                    ]
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "15", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "15", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "15", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "15", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "Thirty five healthy potential participants were enrolled at the clinical study site. Four were screen failures, and one was a back up participant who did not participate. Therefore, 30 participants were randomized.", 
                "recruitment_details": "Recruitment was conducted in the U.S at 1 study site. The first participant was enrolled in July 2012."
            }, 
            "point_of_contact": {
                "email": "leman_yel@baxter.com", 
                "name_or_title": "Leman Yel, MD, Medical Director, Biotherapeutics", 
                "organization": "Baxter Healthcare Corporation"
            }, 
            "reported_events": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Participants who received simultaneous infusions of:\nGLASSIA at 0.04 mL/kg/min\nPlacebo at 0.2 mL/kg/min", 
                            "title": "GLASSIA Infusion Rate- 0.04 mL/kg/Min"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Participants who received simultaneous infusions of:\nGLASSIA at 0.2 mL/kg/min\nPlacebo at 0.04 mL/kg/min", 
                            "title": "GLASSIA Infusion Rate- 0.2 mL/kg/Min"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "30"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "4", 
                                                "@subjects_at_risk": "30"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@events": "1", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "30"
                                                }, 
                                                {
                                                    "@events": "2", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "30"
                                                }
                                            ], 
                                            "sub_title": "Back Pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@events": "2", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "30"
                                                }, 
                                                {
                                                    "@events": "0", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "30"
                                                }
                                            ], 
                                            "sub_title": "Pain In Extremity"
                                        }
                                    ]
                                }, 
                                "title": "Musculoskeletal and connective tissue disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@events": "7", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "6", 
                                                    "@subjects_at_risk": "30"
                                                }, 
                                                {
                                                    "@events": "5", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "3", 
                                                    "@subjects_at_risk": "30"
                                                }
                                            ], 
                                            "sub_title": "Headache"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@events": "2", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "30"
                                                }, 
                                                {
                                                    "@events": "1", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "30"
                                                }
                                            ], 
                                            "sub_title": "Dizziness"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_vocab": "MedDRA (Unspecified)", 
                    "frequency_threshold": "5"
                }, 
                "time_frame": "Throughout the study period of 105 days per participant"
            }
        }, 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Alpha1-antitrypsin Deficiency", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": "Alpha 1-Antitrypsin Deficiency"
        }, 
        "detailed_description": {
            "textblock": "To achieve proper masking, 30 participants were randomly assigned to receive either GLASSIA\n      at 0.04 mL/kg/min with a simultaneous administration of placebo (2.5% human albumin in\n      normal saline) at 0.2 mL/kg/min (Cohort 1) or GLASSIA at 0.2 mL/kg/min with a simultaneous\n      administration of placebo at 0.04 mL/kg/min (Cohort 2) on Day 1.\n\n      Two weeks later (Day 15), the same participants received the second infusion with the\n      opposite rate of GLASSIA infusion and the corresponding masking placebo infusion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18 to 65 years of age inclusive, at the time of screening\n\n          -  Body mass index (BMI) in the range of 19.0 to 32.0 kg/m2 (inclusive) and body weight\n             >= 50 kg at the time of screening\n\n          -  Healthy subject with no clinical evidence of acute and/or chronic disease and no\n             clinically significant abnormalities on hematology panel, clinical chemistry panel,\n             urinalysis, or electrocardiogram (ECG) at the time of screening\n\n          -  Negative drug screen test at screening. Subject must agree to refrain from heavy\n             alcohol consumption (defined as more than 2 drinks per day on a regular basis) and\n             use of narcotic drugs or illegal substances for at least 2 weeks prior to screening\n             and throughout the course of the study. Subject must also agree to drug screen\n             testing at the discretion of the investigator at any time during the course of the\n             study.\n\n          -  If female of childbearing potential, subject presents with a negative serum pregnancy\n             test and agrees to employ adequate birth control measures for the duration of the\n             study\n\n          -  If male, the subject must agree to use an acceptable form of birth control throughout\n             the study and for at least 90 days after dosing. Additionally, the subject must agree\n             to abstain from sperm donation for 90 days after the last administration of\n             investigational product.\n\n          -  Subject is willing and able to comply with the requirements of the protocol\n\n        Exclusion Criteria:\n\n          -  Known history of OR positive serological evidence at the time of screening for\n             hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), Parvovirus\n             B19 (PVB19) or human immunodeficiency virus (HIV) type 1/2 infection\n\n          -  Known history of hypersensitivity or adverse reactions (e.g. urticaria, breathing\n             difficulty, severe hypotension, or anaphylaxis) following administration of blood or\n             blood components\n\n          -  Documented immunoglobulin A (IgA) deficiency (<7 mg/dL at screening)\n\n          -  Evidence of uncontrolled hypertension (systolic blood pressure of >160 mm Hg, and/or\n             diastolic blood pressure of >100 mm Hg despite anti-hypertensive medications)\n\n          -  Subject is nursing or intends to begin nursing during the course of the study\n\n          -  Subject has participated in a clinical trial and has received an investigational\n             product within 60 days prior to screening\n\n          -  Subject has a planned medical procedure within the study period\n\n          -  Any clinically significant medical, psychiatric, or cognitive illness or recreational\n             drug/alcohol use that, in the opinion of the investigator, may impede the subject's\n             ability to comply with the study procedures, pose increased risk to the subject's\n             safety, or confound the interpretation of study results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2012", 
        "firstreceived_results_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651351", 
            "org_study_id": "471201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.", 
                "intervention_name": "Alpha1-proteinase inhibitor", 
                "intervention_type": "Biological", 
                "other_name": "GLASSIA"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "Intravenous administration", 
                "intervention_name": "Placebo: Human albumin 2.5%", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin", 
                "Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Condition:", 
            "for this study", 
            "Focus", 
            "volunteers"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66211"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 4 Double-Blind Study to Assess the Safety and Tolerability of Intravenous Administration of GLASSIA in Healthy Adult Volunteers", 
        "overall_official": {
            "affiliation": "Baxter Healthcare Corporation", 
            "last_name": "Leman Yel, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 and Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651351"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of infusions with temporally associated AEs with an onset time during or within 1 hour of infusion completion, regardless of causality assessment", 
                "measure": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion", 
                "safety_issue": "Yes", 
                "time_frame": "Within 1 hour of infusion completion"
            }, 
            {
                "description": "Number of infusions with temporally associated AEs with an onset time during or within 24 hours of infusion completion, regardless of causality assessment", 
                "measure": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion", 
                "safety_issue": "Yes", 
                "time_frame": "Within 24 hours of the end of infusion"
            }, 
            {
                "description": "Number of infusions with temporally associated AEs with an onset time during or within 72 hours of infusion completion, regardless of causality assessment", 
                "measure": "Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion", 
                "safety_issue": "Yes", 
                "time_frame": "Within 72 hours of the end of infusion"
            }, 
            {
                "description": "Number of AEs that occurred during an infusion and were deemed related to study product administration", 
                "measure": "Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 and Day 15"
            }, 
            {
                "description": "Number of AEs that occurred between 72 hours and 14 day following an infusion and were deemed related to study product administration", 
                "measure": "Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion", 
                "safety_issue": "Yes", 
                "time_frame": "72 hours post infusion to 14 days post infusion"
            }, 
            {
                "description": "Number of participants with seroconversion", 
                "measure": "Number of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA", 
                "safety_issue": "Yes", 
                "time_frame": "105 days"
            }
        ], 
        "source": "Baxter Healthcare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baxter Healthcare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}